<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02441101</url>
  </required_header>
  <id_info>
    <org_study_id>201409760</org_study_id>
    <nct_id>NCT02441101</nct_id>
  </id_info>
  <brief_title>Right Ventricular Septal Pacing in Patients With Right Bundle Branch Block and Heart Failure (The SPARK Trial)</brief_title>
  <acronym>SPARK</acronym>
  <official_title>Right Ventricular Septal Pacing in Patients With Right Bundle Branch Block and Heart Failure, a Pilot Clinical Trial (The SPARK Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael C. Giudici</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study has been designed to test whether a new pacing therapy would lead to
      improvement in heart function, symptoms and quality of life in a specific group of heart
      failure patients. This group has a unique electrical conduction problem (Right Bundle Branch
      Block) that did not respond well to the current available pacing therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot clinical trial will be a randomized single blinded cross over trial. Each subject
      will undergo three study stages. Subject will be randomized initially to either of the two
      arms; experimental or placebo, and then will be followed up for 3 months for the first stage
      to assess outcomes. In the second stage, both arms transition to a two months, intervention
      free, wash out period. Finally, at the third stage both arms will cross over and subject will
      be followed up for an additional 3 months for outcomes assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive reverse left ventricular remodeling, defined as increase in LV Ejection Fraction &gt;15%</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic: QRS duration</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic: LV end-systolic and diastolic diameters and volumes</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic: RV size and function</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic: severity of mitral and tricuspid valve regurgitation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic: estimated pulmonary artery systolic pressure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic: Inter-ventricular conduction delay</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure symptoms (NYHA functional class).</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking distance (6 minute walk test)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Minnesota living with heart failure questionnaire)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory: Plasma NT-proBNP</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory: Plasma Sodium</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory: Plasma BUN and Creatinine</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular arrhythmia burden. An episode is defined as ventricular tachycardia or fibrillation that requires anti-tachycardia pacing therapy, defibrillation or lasts &gt;30 seconds</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Right Bundle-Branch Block</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>RV DDD(R)-60 with AV optimization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RBBB pacing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RV DDD(R)-60</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard demand pacing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RV DDD(R)-60 with AV optimization</intervention_name>
    <description>Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG</description>
    <arm_group_label>RV DDD(R)-60 with AV optimization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RV DDD(R)-60</intervention_name>
    <description>AV settings programmed to minimize RV pacing - standard demand pacing programming.</description>
    <arm_group_label>RV DDD(R)-60</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cardiomyopathy; ischemic or non-ischemic on optimal medical therapy per current heart
             failure treatment guidelines for at least 3 months.

          -  LVEF &lt; 35% by trans-thoracic echocardiogram assessment

          -  Prior implantation of pacemaker/defibrillator with at least an atrial and RV mid
             septal lead. Atrial lead can be waived if RV lead has atrial sensing capabilities*

          -  Normal sinus rhythm at enrollment

          -  RBBB with QRS duration &gt;120 msec on 12 lead surface EKG.

          -  PR interval &lt;250 msec on 12 lead surface EKG

               -  Subjects with biventricular pacemaker/ICD will be eligible for enrollment if
                  their LV lead pacing function has been turned off by the subject's primary
                  cardiologist prior to study enrollment for at least 3 months (this could be due
                  to lead malfunction or the decision to deactivate the LV pacing therapy for any
                  reason per primary cardiologist discretion)

        Exclusion Criteria:

          -  Age younger than 18 years old

          -  Pregnancy

          -  Acute Myocardial infarction within 6 months of entry into the study

          -  Inotrope dependent heart failure condition

          -  Left ventricular assist device or heart transplantation

          -  Any other known conditions other than heart failure that could limit survival to &lt; 6
             months.

          -  Atrial fibrillation or flutter burden &gt;10% of the time within the last 6 months

          -  Atrioventricular node disease that requires ventricular pacemaker support &gt;10% of the
             time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael C Giudici, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael C Giudici, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Belal O Al Khiami, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prashant D Bhave, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael C Giudici, MD</last_name>
    <phone>319-353-8153</phone>
    <email>michael-c-giudici@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ghanshym O Shantha, MBBS</last_name>
    <phone>319-353-8153</phone>
    <email>belal-alkhiami@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael C Giudici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Belal O Al Khiami, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Michael C. Giudici</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Cardiac Resynchronization therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Bundle-Branch Block</mesh_term>
    <mesh_term>Heart Block</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

